Nexalin Technology (NASDAQ:NXL) versus ENDRA Life Sciences (NASDAQ:NDRA) Head-To-Head Comparison

Nexalin Technology (NASDAQ:NXL) and ENDRA Life Sciences (NASDAQ:NDRA) are both small-cap business services companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, institutional ownership, analyst recommendations, profitability, earnings, dividends and risk.

Institutional & Insider Ownership

0.6% of Nexalin Technology shares are owned by institutional investors. Comparatively, 1.2% of ENDRA Life Sciences shares are owned by institutional investors. 24.0% of Nexalin Technology shares are owned by company insiders. Comparatively, 0.0% of ENDRA Life Sciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Risk and Volatility

Nexalin Technology has a beta of 3.5, meaning that its stock price is 250% more volatile than the S&P 500. Comparatively, ENDRA Life Sciences has a beta of 0.74, meaning that its stock price is 26% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of current ratings and price targets for Nexalin Technology and ENDRA Life Sciences, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nexalin Technology	0	0	1	0	3.00
ENDRA Life Sciences	0	0	1	0	3.00

Nexalin Technology currently has a consensus price target of $3.00, indicating a potential downside of 26.83%. ENDRA Life Sciences has a consensus price target of $700,000.00, indicating a potential upside of 11,764,605.88%. Given ENDRA Life Sciences’ higher probable upside, analysts plainly believe ENDRA Life Sciences is more favorable than Nexalin Technology.

Earnings and Valuation

This table compares Nexalin Technology and ENDRA Life Sciences”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nexalin Technology	$162,078.00	325.36	-$4.65 million	($0.64)	-6.41
ENDRA Life Sciences	N/A	N/A	-$10.06 million	($901.15)	-0.01

Nexalin Technology has higher revenue and earnings than ENDRA Life Sciences. Nexalin Technology is trading at a lower price-to-earnings ratio than ENDRA Life Sciences, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Nexalin Technology and ENDRA Life Sciences’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Nexalin Technology	-3,407.98%	-187.59%	-167.21%
ENDRA Life Sciences	N/A	-127.39%	-103.77%

About Nexalin Technology

Nexalin Technology, Inc., a medical device company, designs and develops neurostimulation products for the treatment of mental health in the United States and China. The company designs and develops Generation 2 and Generation 3, that is in clinical trials for the treatment of substance abuse issues related to opiate, cocaine, alcohol abuse, alzheimer's disease, and dementia. It also licenses and sells Nexalin Device, a non-invasive and undetectable to the human body that can provide relief to its afflicted with mental health issues. The company is based in Houston, Texas.

About ENDRA Life Sciences

ENDRA Life Sciences Inc. develops technologies to improve the capabilities of clinical diagnostic ultrasound. The company is developing thermo-acoustic enhanced ultrasound technology that uses radio frequency pulses to generate ultrasonic waves in tissue to create high-contrast images for use in the treatment of nonalcoholic fatty liver disease, as well as in tissue composition, temperature monitoring, vascular imaging, and tissue perfusion. It has a collaborative research agreement with General Electric Company. ENDRA Life Sciences Inc. was incorporated in 2007 and is based in Ann Arbor, Michigan.